Keith Gottesdiener's most recent trade in Prime Medicine Inc was a trade of 100,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 100,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 05 Dec 2024 | 100,000 | 200,000 | - | - | Stock Option (right to buy) | ||
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 08 Oct 2024 | 226,925 | 682,259 | - | 0 | Common Stock | ||
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 08 Oct 2024 | 226,925 | 50,241 | - | 0 | Common Stock | ||
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 05 Jun 2024 | 250,000 | 277,166 | - | 0 | Common Stock | ||
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 05 Jun 2024 | 250,000 | 2,310,837 | - | 0 | Common Stock | ||
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 25 Feb 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | ||
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 12,547 | 12,547 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 8,111 | 32,830 (0%) | 0% | 0 | Common Stock | |
| Prime Medicine Inc | Keith Gottesdiener | Director, See Remarks | 31 Mar 2023 | 497,738 | 497,738 | - | - | Stock Option (right to buy) | ||
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 12,790 | 12,790 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 7,737 | 24,719 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 12,089 | 12,089 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,029 | 16,982 (0%) | 0% | 0 | Common Stock |